How big is the Europe Glaucoma Therapeutics Market?

The Europe Glaucoma Therapeutics Market is valued at US$ 1,529.83 Million in 2023, it is projected to reach US$ 1,930.78 Million by 2031.

What is the CAGR for Europe Glaucoma Therapeutics Market by (2023 - 2031)?

As per our report Europe Glaucoma Therapeutics Market, the market size is valued at US$ 1,529.83 Million in 2023, projecting it to reach US$ 1,930.78 Million by 2031. This translates to a CAGR of approximately 3.0% during the forecast period.

What segments are covered in this report?

The Europe Glaucoma Therapeutics Market report typically cover these key segments- 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物）适应症（开角型青光眼、闭角型青光眼）分销渠道（医院药房、零售药房、网上药房）

What is the historic period, base year, and forecast period taken for Europe Glaucoma Therapeutics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Glaucoma Therapeutics Market report: 2025-2031 2023 2021-2023

Who are the major players in Europe Glaucoma Therapeutics Market?

The Europe Glaucoma Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: Alcon AG ; AbbVie Inc ; Bausch & Lomb Inc ; Viatris Inc ; Novartis AG ; Sun Pharmaceutical Industries Ltd ; Teva Pharmaceuticals Industries Ltd ; Thea Pharma Inc ; Santen Pharmaceutical Co., Ltd

Who should buy this report?

The Europe Glaucoma Therapeutics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the Europe Glaucoma Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.

欧洲青光眼治疗市场（主要地区、市场参与者、规模和份额）预测至 2031 年

2023 年欧洲青光眼治疗市场价值为 15.2983 亿美元，预计到 2031 年将达到 19.3078 亿美元；预计 2023 年至 2031 年的复合年增长率为 3.0%。

越来越多的产品发布、合作和收购推动了欧洲青光眼治疗市场的发展

青光眼治疗制造商正在实施战略联盟、地域扩张、合作伙伴关系、并购和产品/服务发布等战略，以标志其在市场上的地位。

2024 年 3 月，专门从事创新眼部药物输送技术的公司 MediPrint Ophthalmics 宣布成功完成其 2b 期青光眼 SIGHT-2 研究。 2023 年 12 月，美国食品药品监督管理局 (FDA) 批准了 Glaukos Corporation 的 iDose TR（曲伏前列素前房植入物）75 mcg 的新药申请 (NDA)，这是一种前列腺素类似物，用于降低眼高压 (OHT) 或开角型青光眼 (OAG) 患者的眼压。该药物获准每只眼睛单次给药。2022 年 11 月，爱尔康收购了 Aerie Pharmaceuticals, Inc. 通过此次交易，爱尔康获得了 Rocklatan（奈他舒地尔和拉坦前列素滴眼液）0.02%/0.005%；Rhopressa（奈他舒地尔滴眼液）0.02%；AR-15512，一款用于治疗干眼症的 3 期候选产品；以及一系列临床前和临床眼科候选药物。 Rocklatan 和 Rhopressa 是 Rho 激酶抑制剂，用于降低开角型青光眼或眼高压患者的眼压升高。此次收购使爱尔康在扩大其产品组合方面迈出了一步，将青光眼、视网膜和眼表疾病治疗纳入其中。2022 年 3 月，强生视力保健公司获得 FDA 批准其新款 ACUVUE Theravision，这是一种含有抗组胺药酮替芬（每片 19 µg）的隐形眼镜。含酮替芬的 ACUVUE Theravision 是同类产品中的首款，旨在为出现过敏性眼痒的隐形眼镜使用者提供全新的佩戴体验。此类产品发布、合作和收购对青光眼治疗市场的增长做出了重大贡献。

欧洲青光眼治疗市场概览

欧洲青光眼治疗市场分为德国、法国、英国、西班牙、意大利和欧洲其他地区。德国和意大利等国家为该地区的市场贡献了相当大的份额，而法国、英国和西班牙等国家则可能为青光眼治疗市场参与者带来巨大的增长机会。欧洲青光眼治疗市场的增长归因于随着人口老龄化加剧，青光眼病例数量不断上升。德国是青光眼发病率较高的国家。根据萨贝尔视力恢复中心 (SAVIR) 的数据，该国约有 50 万人患有青光眼。然而，专家估计，由于存在未报告的病例，实际数字可能要高得多。近 10% 的青光眼患者最终会出现严重的视力障碍；尽管如此，几乎没有人会完全失明。根据联邦统计局 (Destatis) 的数据，截至 2021 年底，德国 67 岁及以上人口为 1620 万，预计到 2060 年这一数字将上升到 2160 万。罹患青光眼和其他眼部疾病的概率可能会随着年龄的增长而增加。因此，老年人口激增导致青光眼患病率显著上升，从而推动了德国各地对青光眼治疗药物的需求。

欧洲青光眼治疗市场收入及 2031 年预测（百万美元）

欧洲青光眼治疗市场细分

欧洲青光眼治疗市场按药物类别、适应症、分销渠道和国家/地区分类。

根据药物类别，欧洲青光眼治疗市场分为β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物等。前列腺素类似物在2023年占据最大市场份额。

就适应症而言，欧洲青光眼治疗市场分为开角型青光眼、闭角型青光眼等。开角型青光眼在2023年占据最大市场份额。

按分销渠道，欧洲青光眼治疗市场分为医院药房、零售药房和网上药房。医院药房在2023年占据最大市场份额。

按国家/地区，欧洲青光眼治疗市场分为德国、法国、意大利、英国、西班牙和欧洲其他地区。 2023 年，德国占据了欧洲青光眼治疗市场的主导地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是欧洲青光眼治疗市场的主要公司。

Europe Glaucoma Therapeutics Strategic Insights

Strategic insights for Europe Glaucoma Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-glaucoma-therapeutics-market-strategic-framework.webp

Get more information on this report

Europe Glaucoma Therapeutics Report Scope

Report Attribute	Details
Market size in 2023	US$ 1,529.83 Million
Market Size by 2031	US$ 1,930.78 Million
Global CAGR (2023 - 2031)	3.0%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 药物类别（β受体阻滞剂、α肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物） By 适应症（开角型青光眼、闭角型青光眼） By 分销渠道（医院药房、零售药房、网上药房）
Regions and Countries Covered	欧洲（英国、德国、法国、西班牙、意大利、欧洲其他地区）欧洲（英国、德国、法国、西班牙、意大利、欧洲其他地区）
Market leaders and key company profiles	Alcon AG AbbVie Inc Bausch & Lomb Inc Viatris Inc Novartis AG Sun Pharmaceutical Industries Ltd Teva Pharmaceuticals Industries Ltd Thea Pharma Inc Santen Pharmaceutical Co., Ltd

Get more information on this report

Europe Glaucoma Therapeutics Regional Insights

The regional scope of Europe Glaucoma Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.